Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of Renal Outcomes from Contrast-Induced Nephropathy with Amino Acids vs Saline in Critically Ill Patients
TCTR20260118006Phase 3Not yet recruiting
- Sponsor
- N/A
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of Travesol in contrast-induced nephropathy (CIN) (2 arms), sponsored by N/A. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
Travesol
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on TCTR20260118006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260118006.